香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 1466） 正面盈利預告 本 公 告 乃 由 佰 金 生 命 科 學 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）根 據 香 港 聯 合 交 易 所 有 限 公 司（「 聯 交 所 」）證 券 上 市 規 則（「 上 市 規 則 」）第 13.09 (2) (a)條 及 香港 法例 第571 章 證券 及期 貨條 例 第XIVA 部 項下 之內 幕消 息 條文 （ 定義見上市規則 ）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 根據對本集團的未經審核綜合管理賬目作出的初 ...

Core Insights - Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology R&D platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. focuses on circRNA technology platform development and innovative drug development, also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] Group 2: Collaboration Focus Areas - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Baijin's exosome and cell platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, cerebral infarction, Alzheimer's, and Parkinson's diseases [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

Group 1 - Company Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity acquisition, aiming to establish a leading global circRNA technology research and development platform [1] - The agreement is set to expire on December 31, 2026, and either party can terminate the agreement with a 10-day notice [1] Group 2 - Youhuan is a biopharmaceutical company focused on circRNA technology platform development and innovative drug development, also providing CRO services [2] - Youhuan has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] - The company is engaged in deep cooperation with large enterprises in the international drug development field and has signed contracts in certain cell application areas with a global multinational company [2] Group 3 - The initial focus of the collaboration will include exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Research will also target circRNA and exosome drug delivery technologies, developing new delivery systems based on exosome and cell platforms [3] - The development of engineered exosome drugs and cell drugs for cardiovascular and tissue repair applications, as well as treatments for neurodegenerative diseases like Alzheimer's and Parkinson's, is also a priority [3] - The collaboration aims to develop precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

Core Insights - Baijin Life Sciences (01466.HK) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology research platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan is a dual-driven biopharmaceutical company focusing on circRNA technology platform research and innovative drug development, while also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for its proprietary "Circular RNAs and Preparation Methods" and a Chinese invention patent for a method based on ribozyme self-splicing [2] Group 2: Collaboration Focus - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Youhuan's platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, stroke, and neurodegenerative diseases like Alzheimer's and Parkinson's [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 1466） 自願公告 策略合作框架協議 此乃佰金生命科學控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）作出 之自願公告，旨在讓本公司股東（「股東」）及潛在投資者了解本集團的最新業務發 展情況。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東及潛在投資者，本公司間 接全資附屬公司北京佰金生物科技有限公司（「北京佰金」）與優環（ 蘇州 ）生物醫藥 科技有限公司（「優環生物」）簽訂策略合作框架協議（「合作框架協議」），據此，北 京佰金將透過認購優環生物股權的方式對優環生物進行投資，旨在打造全球領先 的 環狀 RNA (circ RNA) 技 術研 發 平台 ...

佰金生命科学(01466)发布公告，本公司股本中每股面值0.02港元的股份于香港联合交易所有限公司(联 交所)主板上市的每手买卖单位将由32000股更改为8000股，自2025年12月8日(星期一)上午九时正起生效 (更改每手买卖单位)。 ...

Core Viewpoint - Baijin Life Sciences (01466) announced a change in the trading unit of its shares listed on the Hong Kong Stock Exchange, reducing the trading unit from 32,000 shares to 8,000 shares, effective from December 8, 2025 [1] Summary by Category - **Company Announcement** - Baijin Life Sciences will change the trading unit of its shares from 32,000 to 8,000 shares [1]

Core Viewpoint - Baijin Life Sciences (01466.HK) announced a change in the trading unit of its shares on the Hong Kong Stock Exchange, reducing the minimum trading unit from 32,000 shares to 8,000 shares, effective from December 8, 2025 [1] Summary by Category - **Company Announcement** - The company will adjust the trading unit of its shares from 32,000 to 8,000 shares [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （股份代號： 1466） （於開曼群島註冊成立之有限公司） 更改每手買賣單位 佰金生命科學控股有限公司（「本公司」）董事（「董會」）會（「董事會」）謹此宣佈，本 公司股本中每股面值0.02港元的股份（「股份」）於香港聯合交易所有限公司（「聯交 所」）主板上市的每手買賣單位將由32,000股更改為8,000股，自2025年12月8日（ 星 期一 ）上午九時正起生效（「更改每手買賣單位」）。 按股份於緊接本公告日期前在聯交所所報收市價每股0.53港元計算，現有每手買 賣單位32,000股股份之市值為16,960港元。於更改每手買賣單位生效後，股份將以 每手買賣單位8,000股進行買賣，而每手買賣單位8,000股股份之相應市 ...

Core Viewpoint - Baijin Life Sciences (01466.HK) will hold a board meeting on November 27, 2025, to approve the unaudited interim results for the six months ending September 30, 2025, and to consider the payment of an interim dividend, if any [1] Group 1 - The board meeting is scheduled for November 27, 2025 [1] - The meeting will focus on approving the interim results for the six months ending September 30, 2025 [1] - The company will also consider the potential payment of an interim dividend [1]